Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Micreos Human Health B V maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are distributed across 2 distinct examiners, showing a lack of examiner overlap in the current workload. This distribution requires the applicant to navigate the specific requirements of multiple individuals simultaneously.
The prosecution is further divided across 2 distinct art units, which suggests that the 2 pending office actions may involve different technical sub-specialties within the broader Biotechnology & Pharmaceuticals field. LANKFORD JR, LEON B is the busiest examiner for the company, currently managing 1 busiest examiner pending office action. This accounts for half of the total pending actions for the portfolio.
For a patent practitioner, the presence of 2 distinct examiners and 2 distinct art units for only 2 pending office actions indicates a fragmented prosecution landscape. Strategies must be tailored to the specific tendencies of LANKFORD JR, LEON B and the other examiner involved. Monitoring these 2 pending office actions involves tracking two separate paths through the patent office's administrative structure.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 1 | 70.0% | +31.5% |
| MOSS, NATALIE M | 1 | 30.7% | +17.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16753162 | Treatment of a Condition Associated with Infection with an Oncogenic Bacterium | MOSS, NATALIE M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18840549 | A CHIMERIC ENDOLYSIN POLYPEPTIDE | LANKFORD JR, LEON B | — |
| 16753162 | Treatment of a Condition Associated with Infection with an Oncogenic Bacterium | MOSS, NATALIE M | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18840549 | A CHIMERIC ENDOLYSIN POLYPEPTIDE | LANKFORD JR, LEON B | 1657 | §102 | Non-Final OA | — | Pending | Aug 22, 2024 |
| 16753162 | Treatment of a Condition Associated with Infection with an Oncogenic Bacterium | MOSS, NATALIE M | 1653 | §103§112 | Non-Final OA | — | Pending | Apr 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMicreos Human Health B V has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Leon B Lankford Jr. has the most, with 1 of Micreos Human Health B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
